Published in J Biol on April 15, 2009
Proteomic identification of multitasking proteins in unexpected locations complicates drug targeting. Nat Rev Drug Discov (2009) 1.21
Monocarbonyl curcumin analogues: heterocyclic pleiotropic kinase inhibitors that mediate anticancer properties. J Med Chem (2013) 0.80
Delivery as nanoparticles reduces imatinib mesylate-induced cardiotoxicity and improves anticancer activity. Int J Nanomedicine (2015) 0.76
Large-scale bioactivity analysis of the small-molecule assayed proteome. PLoS One (2017) 0.75
Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome? Curr Neuropharmacol (2015) 0.75
Detecting similar binding pockets to enable systems polypharmacology. PLoS Comput Biol (2017) 0.75
Transport of drugs from blood vessels to tumour tissue. Nat Rev Cancer (2017) 0.75
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol (2007) 6.56
Translation of the Philadelphia chromosome into therapy for CML. Blood (2008) 4.74
Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med (2008) 3.64
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood (2007) 3.59
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer (2007) 3.32
Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A (2008) 2.06
The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2). BMC Struct Biol (2009) 1.18
The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl. Curr Opin Cell Biol (2009) 1.11
Imatinib as a novel therapeutic approach for fibrotic disorders. Rheumatology (Oxford) (2008) 1.10
Genome-wide identification of genes required for yeast growth under imatinib stress: vacuolar H+-ATPase function is an important target of this anticancer drug. OMICS (2009) 0.91
Coordinated regulation of life and death by RB. Nat Rev Cancer (2003) 2.39
Regulation of F-actin-dependent processes by the Abl family of tyrosine kinases. J Cell Sci (2003) 2.10
Modulation of the F-actin cytoskeleton by c-Abl tyrosine kinase in cell spreading and neurite extension. J Cell Biol (2002) 1.72
Targeting the RB-pathway in cancer therapy. Clin Cancer Res (2010) 1.54
Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics. Int J Cancer (2006) 1.53
A myogenic differentiation checkpoint activated by genotoxic stress. Nat Genet (2002) 1.53
Double-strand DNA breaks recruit the centromeric histone CENP-A. Proc Natl Acad Sci U S A (2009) 1.47
Interaction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatin. Proc Natl Acad Sci U S A (2003) 1.47
Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage. Mol Cell Biol (2006) 1.45
BCR-ABL-transformed GMP as myeloid leukemic stem cells. Proc Natl Acad Sci U S A (2008) 1.34
c-Abl phosphorylates Dok1 to promote filopodia during cell spreading. J Cell Biol (2004) 1.26
Selection of mammalian cells based on their cell-cycle phase using dielectrophoresis. Proc Natl Acad Sci U S A (2007) 1.23
Signal-dependent protection from apoptosis in mice expressing caspase-resistant Rb. Nat Cell Biol (2002) 1.22
RB restricts DNA damage-initiated tumorigenesis through an LXCXE-dependent mechanism of transcriptional control. Mol Cell (2011) 1.16
Induction of cell retraction by the combined actions of Abl-CrkII and Rho-ROCK1 signaling. J Cell Biol (2008) 1.13
Modulation of DNA damage-induced apoptosis by cell adhesion is independently mediated by p53 and c-Abl. Proc Natl Acad Sci U S A (2003) 1.12
The CML stem cell: evolution of the progenitor. Cell Cycle (2009) 1.10
Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy. Int J Hematol (2008) 1.00
Abl tyrosine kinase promotes dorsal ruffles but restrains lamellipodia extension during cell spreading on fibronectin. Mol Biol Cell (2007) 1.00
Tumor necrosis factor alpha-induced apoptosis requires p73 and c-ABL activation downstream of RB degradation. Mol Cell Biol (2004) 1.00
cAMP-mediated inhibition of DNA replication and S phase progression: involvement of Rb, p21Cip1, and PCNA. Mol Biol Cell (2005) 0.97
A functional connection between pRB and transforming growth factor beta in growth inhibition and mammary gland development. Mol Cell Biol (2009) 0.97
Ascorbate up-regulates MLH1 (Mut L homologue-1) and p73: implications for the cellular response to DNA damage. Biochem J (2002) 0.96
Tumor promotion by caspase-resistant retinoblastoma protein. Proc Natl Acad Sci U S A (2005) 0.94
Blockade of tumor necrosis factor-induced Bid cleavage by caspase-resistant Rb. J Biol Chem (2007) 0.93
An evolutionarily acquired genotoxic response discriminates MyoD from Myf5, and differentially regulates hypaxial and epaxial myogenesis. EMBO Rep (2011) 0.92
Death by Abl: a matter of location. Curr Top Dev Biol (2004) 0.92
DNA damage-induced cell death: lessons from the central nervous system. Cell Res (2008) 0.91
Ionizing radiation induces ATM-independent degradation of p21Cip1 in transformed cells. J Biol Chem (2009) 0.91
Separation of anti-proliferation and anti-apoptotic functions of retinoblastoma protein through targeted mutations of its A/B domain. PLoS One (2006) 0.91
Exclusion of c-Abl from the nucleus restrains the p73 tumor suppression function. J Biol Chem (2003) 0.91
Interplay between kinase domain autophosphorylation and F-actin binding domain in regulating imatinib sensitivity and nuclear import of BCR-ABL. PLoS One (2011) 0.90
Radiation dose-dependent maintenance of G(2) arrest requires retinoblastoma protein. Cell Cycle (2002) 0.89
Modulation of human checkpoint kinase Chk1 by the regulatory beta-subunit of protein kinase CK2. Oncogene (2003) 0.87
Apoptotic function of human PMS2 compromised by the nonsynonymous single-nucleotide polymorphic variant R20Q. Proc Natl Acad Sci U S A (2008) 0.87
Trp53 deficiency protects against acute intestinal inflammation. J Immunol (2013) 0.86
Murine xenograft model for human uterine fibroids: an in vivo imaging approach. Reprod Sci (2009) 0.85
Uracil DNA N-glycosylase promotes assembly of human centromere protein A. PLoS One (2011) 0.84
Systems analysis of quantitative shRNA-library screens identifies regulators of cell adhesion. BMC Syst Biol (2008) 0.84
Eph tumour suppression: the dark side of Gleevec. Nat Cell Biol (2006) 0.83
Nuclear expression of β-catenin promotes RB stability and resistance to TNF-induced apoptosis in colon cancer cells. Mol Cancer Res (2013) 0.83
Platelet-derived growth factor C is upregulated in human uterine fibroids and regulates uterine smooth muscle cell growth. Biol Reprod (2009) 0.83
Mitotic phosphorylation rescues Abl from F-actin-mediated inhibition. J Biol Chem (2005) 0.82
Persistent inhibition of ABL tyrosine kinase causes enhanced apoptotic response to TRAIL and disrupts the pro-apoptotic effect of chloroquine. PLoS One (2013) 0.81
β-Catenin-dependent lysosomal targeting of internalized tumor necrosis factor-α suppresses caspase-8 activation in apoptosis-resistant colon cancer cells. Mol Biol Cell (2012) 0.81
Ectopic expression of p73alpha, but not p73beta, suppresses myogenic differentiation. J Biol Chem (2004) 0.81
Reduced focal adhesion kinase and paxillin phosphorylation in BCR-ABL-transfected cells. Cancer (2002) 0.80
Expression profiling of protein tyrosine kinases and their ligand activators in leiomyoma uteri. Syst Biol Reprod Med (2010) 0.79
Effect of hydroxyurea on the promoter occupancy profiles of tumor suppressor p53 and p73. BMC Biol (2009) 0.75